Skip to main content
SpringerLink
Log in

Chemical, Pharmacological, Toxicological and Therapeutic Advances of Deferiprone (L1) and Other Iron and Aluminium Chelators

  • Conference paper
Toxicology - From Cells to Man

Part of the book series: Archives of Toxicology ((TOXICOLOGY,volume 18))

Abstract

A global breakthrough in oral chelation therapy with the a-ketohydroxypyridine chelating drug l,2-dimethyl-3-hydroxypyrid-4-one (LI, INN/BAN: Deferiprone) (Kontoghiorghes 1982) in iron and aluminium overloaded patients has recently been achieved. Since the initiation of clinical trials with LI in 1987 and prior to its recent registration in India, over 800 patients with ten different conditions in 16 countries have received it, in some cases daily for over 6 years. The major toxic side effects, which all appear to be reversible, include agranulocytosis, musculoskeletal and joint pains, zinc deficiency and gastric intolerance. Oral LI appears to be as effective as subcutaneous desferoxamine (DF) in iron and aluminium removal and has low toxicity. Other α-ketohydroxypyridines are also currently being developed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agarwal MB, Gupta SS, Viswanathan C, et al (1992a) Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia. Indian trial. Drugs Today 28 (Suppl A): 107 – 114

    Google Scholar 

  • Anderson WF, Hiller MC (eds) (1975) Development of iron chelators for clinical use. National Institute of Health. Bethesda USA: 1 – 277

    Google Scholar 

  • Brock J, Liceaga J, Kontoghiorghes GJ (1988) The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol 47: 55 – 60

    Article  Google Scholar 

  • Carnelli V, Spadaro C, Stefano V, Battaglioli M, Fossati G, Perri M (1992) LI efficacy and toxicity in poorly compliant and for refractory to desferrioxamine thalassaemia patients: Interim report. Drugs Today. 28 (Suppl A): 119 – 121

    Google Scholar 

  • Cunningham JM, Hunter A, Francis GE, Kontoghiorghes GJ, Hoffbrand AV (1991) Differential cytotoxicity of oral iron chelators and desferrioxamine to human bone marrow haemopoietic progenitor cells in vitro. Brit J Haematol 77 (suppl 1): 381

    Google Scholar 

  • Donfrancesco A, Deb G, Dominici C, Castello MA, Helson L (1990) Effects of a single course of deferoxamine in Neuroblastoma patients. Cancer Res 50: 4929–4930

    PubMed  CAS  Google Scholar 

  • Edwardson JA, Ferrier IN, McArthur FK et al (1992) Alzheimer’s disease and the aluminium hypothesis. In: Aluminium in Chemistry, Biology and Medicine. Nicolini, Zatta PF, Corain B (eds). Raven Press, New York 1: 85 – 96

    Google Scholar 

  • Estrow ZA, Tawa XH, Dube ID et al (1987) In vitro and in vivo effects of deferoxamine in neonatal acute leukaemia. Blood 69: 757 – 761

    Google Scholar 

  • Eybl V, Svihovcov P, Kontensky J, Kontoghiorghes GJ (1992) Interaction of LI, L1NA11 and deferoxamine with Gallium in vivo. Drugs Today 28 (Suppl A): 173 – 175

    CAS  Google Scholar 

  • Ganeshaguru K, Lally KM, Piga A, Hoffbrand AV, Kontoghiorghes GJ (1992) Cytotoxic mechanisms of iron chelators. Drugs Today 28 (Suppl A): 29 – 34

    CAS  Google Scholar 

  • Giordano N, Sancasciani S, Borghi C, Fiorauenti A, Marcolongo P (1986) Antianemic and potential anti-inflammatory activity of desferrioxamine: Possible usefulness in rheumatoid arthritis. Clin Exp Rheumatol 4: 25 – 29

    PubMed  CAS  Google Scholar 

  • Goudsmit R, Kersten MJ (1992) Long term treatment of transfusion hemosiderosis with the oral iron chelator LI. Drugs Today 28 (Suppl A): 133 – 135

    Google Scholar 

  • Halliwell B, Gutteridge JMC, Cross CE (1992). Free radicals, antioxidants and human disease: Where are we now? J Lab Clin Med 119: 598 – 620

    PubMed  CAS  Google Scholar 

  • Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW (1988) Antimalarial properties of orally active iron chelators. Blood 72: 358 – 361

    PubMed  CAS  Google Scholar 

  • Jaeger M, Aul C, Sohngen D, Germing U, Schneider W (1992) Iron overload in polytransfused patients with MDS; Use of LI for oral iron chelation. Drugs Today 28 (Suppl A): 143 – 147

    Google Scholar 

  • Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P (1988) The iron chelators desferrioxamine and l-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacylin synthesis in vitro. Biochem J 254: 239 – 244

    PubMed  CAS  Google Scholar 

  • Kontoghiorghes GJ (1982) The design of orally active iron chelators for the treatment of thalassaemia. PhD thesis, University of Essex, Colchester UK. British Library Microfilm No D66194 /86

    Google Scholar 

  • Kontoghiorghes GJ (1986) Orally active a-ketohydroxypyridine iron chelators: studies in mice. Mol Pharmacol 30: 670 – 673

    PubMed  CAS  Google Scholar 

  • Kontoghiorghes GJ (1990a) Design, properties and effective use of the oral chelator LI and other a-ketohydroxypyridines in the treatment of transfusional iron overload in thalassaemia Ann NY Acad Sci 612: 339 – 350

    Google Scholar 

  • Kontoghiorghes GJ (1990 b) Chelators affecting iron absorption in mice. Arzneim.Forsch/Drug Res. 40:1332–1335

    CAS  Google Scholar 

  • Kontoghiorghes GJ (1992) Advances in oral iron chelation in man. Intern J Haematol 55: 27 – 38

    CAS  Google Scholar 

  • Kontoghiorghes GJ (1993) Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Paediatr 60: 485 – 507

    Article  CAS  Google Scholar 

  • Kontoghiorghes GJ (1993) Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Paediatr 60: 485 – 507

    Article  CAS  Google Scholar 

  • Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV et al (1987a) Effective chelation of iron in ß-thalassaemia with the oral chelator l,2-dimethyl-3-hydroxypyrimid-4-one. Br Med J 295: 1509 – 1512

    Article  CAS  Google Scholar 

  • Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV (1987b) l,2-Dimethyl-3- hydroxypyrid-4-one, an orally active chelator for the treatment of transfusional iron overload. Lancet i: 1294–1295

    Article  Google Scholar 

  • Kontoghiorghes GJ, Barr J, Baillot R (1992) Aluminium mobilisation in renal dialysis patients using the oral chelator l,2„dimethyl„3„hydroxypyrid„4„one (LI). Drugs Today 28 (Suppl A): 183 – 187

    Google Scholar 

  • Kontoghiorghes GJ, Barr J, Baillot R (1994) Studies of aluminium mobilisation in renal dialysis patients using the oral chelator l,2-dimethyl-3-hydroxypyrid-4-one. Arzneim Forsch/Drug Res 44: 522 – 526

    CAS  Google Scholar 

  • Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L. (1993) Selection of a newgeneration of new orally active a-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Amer J Haematol 42: 440 – 444

    Google Scholar 

  • Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV et al (1990c) Long term trial with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4-one (L1). (1) Iron chelation and metabolic studies. Br. J Haematol 76: 295 – 300

    Article  CAS  Google Scholar 

  • Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P (1995) Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. Arzneim Forsch/Drug Res 45: 65 – 69

    CAS  Google Scholar 

  • Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L (1990 b) Pharmacokinetic studies in humans with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharm Ther 48:255–261

    Article  CAS  Google Scholar 

  • Kontoghiorghes GJ, Sheppard LN (1987) Simple synthesis of the potent iron chelators 1- hydroxy-2-methylpyrid-4-ones. Inorg Chim Acta 136: L11 – L12

    Article  CAS  Google Scholar 

  • Kontoghiorghes GJ and Sheppard LN (1989) Process for producing pyrid-4-ones. European Patent Application No: 0335745

    Google Scholar 

  • Kontoghiorghes GJ, Sheppard LN, Hoffbrand AV, Bartlett AN, Barr J (1990a) l-Ethyl-2- methyl-3-hydroxypyrid-4-one (LINEt) A new orally effective iron chelator for the treatment of transfusional iron overload. Blood 76:66a

    Google Scholar 

  • Kontoghiorghes GJ, Weinberg ED (1995) Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 9: 33 – 45

    Article  PubMed  CAS  Google Scholar 

  • Korkina LG, Afanas’ev IB, Deeva IB et al (1992) Free radical status of blood of patients with iron overload: the effect of chelating treatment. Drugs Today 28 (Suppl A): 137 – 141

    Google Scholar 

  • Lin JY, Ling KH (1973) Studies on free amino acids in the seeds of Leucaena Glauca Benth:H[, biological study of mimosine. J Formosan Med Assoc 60: 657 – 664

    Google Scholar 

  • Martell AE, Anderson WF, Badman DG (eds) (1980) Development of iron chelators for clinical use. Amsterdam: Elsevier: 1 – 311

    Google Scholar 

  • Molenda J J, Jones MM, Basinger MA (1994) Enchancement of iron excretion via monoanionic 3-hydroxypyrid-4-ones. J Med Chem 37: 93 – 98

    Article  PubMed  CAS  Google Scholar 

  • Motekaitis RJ, Martell AE (1991) Stabilities of the iron (III) chelates of l,2-dimethyl-3- hydroxy-4-pyridinone and related ligands. Inorg Chim Acta 183: 71 – 80

    Article  CAS  Google Scholar 

  • Nielsen P, Frtjes M, Drescow B, Fischer R, Engelhardt R, Heinrich HC (1992) The iron- decorporating effect of LI in normal and TMH-ferrocene iron loaded rats and in one patient with post-transfusional siderosis as judged by 59Fe-labelling technique. Drugs Today 28 (Suppl A): 45 – 53

    CAS  Google Scholar 

  • Olivieri NF, Brittenham GM, Matsui D et al (1995) Iron-chelation therapy with oral deferiprone in patients with thalassaemia major. N Engl J Med 332: 918 – 922

    Article  PubMed  CAS  Google Scholar 

  • Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB (1986) Iron chelation using subcutaneous infusion of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 36: 466 – 472

    Article  PubMed  CAS  Google Scholar 

  • Politis C, Vrettou H, Fragatou S et al (1993) Reactions to subcutaneous application of iron chelation therapy with desferoxamine. An urgent need for oral chelators. Abstracts, 4th ICOC Limassol, Cyprus 4

    Google Scholar 

  • Porter JB, Weir TB, Marshall L et al (1993) Clinical trials with the orally active hydroxypyridone CP94: Implications for future strategies in iron chelation therapy. Abstracts, 4th ICOC Limassol, Cyprus 18

    Google Scholar 

  • Sheppard L, Kontoghiorghes GJ (1992) Synthesis and metabolism of LI and other novel alpha-ketohydroxypyridine iron chelators and their metal complexes. Drugs Today. 28 (Suppl A): 3 – 10

    CAS  Google Scholar 

  • Sheppard LN and Kontoghiorghes GJ (1993) Competition between deferiprone, desferoxamine and other chelators for iron and the eflFect of other metals. Arzneim. Forsch/DrugRes 43: 659 – 663

    CAS  Google Scholar 

  • Taylor D, Kontoghiorghes GJ (1986) Mobilisation of plutonium and iron from transferrin and ferritin by a-oxohydroxypyridine chelators. Inorg Chim Acta 125: L35 – L38

    Article  CAS  Google Scholar 

  • Tsai WC, Ling KH (1971) Effect of metals on the absorption and excretion of mimosine and 3,4-dihydroxypyridine in rat in vivo. J Formosan Med Assoc 73: 543 – 549

    Google Scholar 

  • Tsai WC, Ling KH (1973) Study of the stability constant of some metal ion chelates of mimosine and 3,4-dihydroxypyridine. J Chin Biol Soc 2: 70 – 86

    CAS  Google Scholar 

  • Tondury P, Kontoghiorghes GJ, Ridolfi„Luthy R et al (1990) LI (l,2-dimethyl-3- hydroxypyrid-4-one) for oral iron chelation in patients with ß-thalassaemia major. Br J Haematol 76: 550 – 553

    Article  PubMed  CAS  Google Scholar 

  • Vreugdenhil G, Kontogfriorghes GJ, Van Eijk HG, Swaak AJG (1991) Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2- dimethyl-3- hydroxypyrid-4-one. Clin Exp Rheumatol 9: 35 – 40

    PubMed  CAS  Google Scholar 

  • Weinberg ED (1984) Iron withholding: a defense against infection and neoplasia. Physiol. Revs 64: 65 – 102

    CAS  Google Scholar 

  • World Health Organisation Bulletin (1983) Community control of hereditary anaemias 61: 63 – 80

    Google Scholar 

  • Zurlo MG, De Stefano P, Borgna-Pignatti C et al (1989) Survival and causes of death in thalassaemia major. Lancet ii: 27 – 29

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Free Hospital School of Medicine, London, NW3 2QG, UK

    G. J. Kontoghiorghes

Authors
  1. G. J. Kontoghiorghes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Interkantonale Kontrollstelle für Heilmittel, Erlachstrasse 8, CH-3000, Bern 9, Switzerland

    Jürg P. Seiler

  2. Department of Pharmacology, Charles University of Prague, 3rd Medical School, Ruská 87, Czech Republic

    Olga Kroftová

  3. Department of Pharmacology, Charles University, Faculty of Medicine, Karlovarská 48, CZ-30166, Pilsen, Czech Republic

    Vladislav Eybl

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kontoghiorghes, G.J. (1996). Chemical, Pharmacological, Toxicological and Therapeutic Advances of Deferiprone (L1) and Other Iron and Aluminium Chelators. In: Seiler, J.P., Kroftová, O., Eybl, V. (eds) Toxicology - From Cells to Man. Archives of Toxicology, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61105-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61105-6_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64696-6

  • Online ISBN: 978-3-642-61105-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation